Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

21.51
-0.3800-1.74%
Volume:1.31M
Turnover:28.42M
Market Cap:2.44B
PE:-8.66
High:22.56
Open:22.15
Low:21.51
Close:21.89
52wk High:30.06
52wk Low:11.25
Shares:113.58M
Float Shares:108.11M
Volume Ratio:0.71
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:4.65
PE(LYR):-8.85

Loading ...

Immunome Director Isaac Barchas Reports Disposal of 36,088 Common Shares Worth $940,453.28

Reuters
·
Aug 11

Immunome, Inc. Expected to Post a Loss of 52 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Immunome Chief Business Officer Horn Kinney Sells 90,616 Common Shares for $2.27 Million

Reuters
·
Aug 07

Immunome Grants Inducement Stock Options for 176,500 Shares at $23.01 to New Hires

Reuters
·
Aug 07

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 07

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Argenx Se (ARGX)

TIPRANKS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Immunome (IMNM) and Incyte (INCY)

TIPRANKS
·
Jul 22

Immunome Price Target Maintained with a $31.00/share by Wedbush

Dow Jones
·
Jul 21

Immunome Begins Phase 1 Trial Dosing of Therapy for Advanced Solid Tumors

MT Newswires Live
·
Jul 20

Immunome announces first patient dosed in Phase 1 IM-3050 trial

TIPRANKS
·
Jul 20

Immunome Notifies Availability of Press Release

Reuters
·
Jul 20

Immunome - Phase 1 Trial to Evaluate Safety and Preliminary Activity of Im-3050

THOMSON REUTERS
·
Jul 20

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating Im-3050, an Fap-targeted Radioligand Therapy, in Patients with Fap-expressing Advanced Solid Tumors

THOMSON REUTERS
·
Jul 20

Immunome (IMNM) NDA Acceptance Puts Valuation Back In Focus

Simply Wall St.
·
Jul 18

Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data

Simply Wall St.
·
Jul 17

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)

TIPRANKS
·
Jul 11

Immunome Chief Business Officer Horn Kinney Disposes of 1,092 Common Shares Worth $27,300

Reuters
·
Jul 10

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

TIPRANKS
·
Jul 09

Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA

TIPRANKS
·
Jul 08

Immunome Flags Press Release on FDA Acceptance of Varegacestat NDA for Desmoid Tumors

Reuters
·
Jul 08